ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 092,11
-0,61%
Dow Jones
39 671,04
-0,51%
DAX
18 680,20
-0,25%
Brent Oil
81,28
-0,31%
Bitcoin
69 466,57
0,52%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ocera Therapeutics, Inc. (MM) (OCRX)

  7. Ocera Therapeutics, Inc. (MM) (OCRX) Actualités

OCRX

Ocera Therapeutics, Inc. (OCRX)

Ocera Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:OCRX
DateHeureSourceTitreSymboleSociété
14/02/201823h54Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
21/12/201722h26Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
21/12/201712h04Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
14/12/201712h01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
13/12/201723h00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
11/12/201716h26Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
11/12/201716h22Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
11/12/201715h55Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
11/12/201715h37Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
11/12/201715h27Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
11/12/201714h52Edgar (US Regulatory)(25-NSE)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
14/11/201723h23Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
13/11/201722h13Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
09/11/201722h25Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
09/11/201722h11Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
03/11/201701h06PR Newswire (US)SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Ocera Therapeutics, Inc. - OCRXNASDAQ:OCRXOcera Therapeutics, Inc. (MM)
02/11/201721h40Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
02/11/201712h14Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
02/11/201711h56GlobeNewswire Inc.Mallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encep...NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
02/11/201711h45PR Newswire (US)Mallinckrodt To Acquire Ocera Therapeutics And OCR-002, Its Proprietary Therapy In Development For Treatment Of Hepatic Encep...NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
20/10/201713h30GlobeNewswire Inc.Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
23/08/201715h05GlobeNewswire Inc.Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
01/08/201722h05GlobeNewswire Inc.Ocera Therapeutics Reports Second Quarter 2017 Financial ResultsNASDAQ:OCRXOcera Therapeutics, Inc. (MM)
01/06/201715h05GlobeNewswire Inc.Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with CirrhosisNASDAQ:OCRXOcera Therapeutics, Inc. (MM)
26/05/201715h05GlobeNewswire Inc.Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, ...NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
09/05/201722h05GlobeNewswire Inc.Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical UpdateNASDAQ:OCRXOcera Therapeutics, Inc. (MM)
03/05/201722h05GlobeNewswire Inc.Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
26/04/201712h03Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
25/04/201722h45Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
17/04/201719h54Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:OCRXOcera Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:OCRX

Dernières Valeurs Consultées

CRTO
KRLUSD
Kryll
COIN
ICEEEUR
iDice
NASDAQ
AAZQSXX
Bofa Finance Llc Issuer ...
EU
COP5E
Euronext Climate Orienta...
BITMOT
778738
Bund Tf 1% Ag25 Eur
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés